Davita-Sullivan Dialysis is a medicare approved dialysis facility center in Sullivan, Indiana and it has 13 dialysis stations. It is located in Sullivan county at 2232 N Hospital Blvd, Suite 1, Sullivan, IN, 47882. You can reach out to the office of Davita-Sullivan Dialysis at (812) 268-5593. This dialysis clinic is managed and/or owned by Davita. Davita-Sullivan Dialysis has the following ownership type - Profit. It was first certified by medicare in January, 2018. The medicare id for this facility is 152685 and it accepts patients under medicare ESRD program.
| Name | Davita-Sullivan Dialysis |
|---|---|
| Location | 2232 N Hospital Blvd, Suite 1, Sullivan, Indiana |
| No. of Dialysis Stations | 13 |
| Medicare ID | 152685 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2232 N Hospital Blvd, Suite 1, Sullivan, Indiana, 47882 | |
| (812) 268-5593 | |
| Not Available |
News Archive
A SHEFFIELD patient has become the first in the world to take part in a new drug research trial aiming to better control secondary breast cancer, or cancer which has spread to other parts of the body including the bones, liver and lungs for longer.
Results from a new study show that amlodipine-based (calcium channel blocker) treatment is much more effective at reducing blood pressure near the heart than a conventional atenolol-based (beta blocker) regimen.
A team of scientists at the Weizmann Institute of Science in Israel revealed that the ability to detect smells predicts recovery and long-term survival in patients who had a severe brain injury. The study, published in the journal Nature, shows that the simple "sniff test," which is inexpensive and convenient, could help doctors to diagnose and develop treatments for patients who have brain injuries and unconsciousness.
Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.
Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.
› Verified 5 days ago
| NPI Number | 1619499225 |
| Organization Name | Sullivan Dialysis |
| Doing Business As | Solidago Dialysis, Llc |
| Address | 2232 N Hospital Blvd Sullivan, Indiana, 47882 |
| Phone Number | (812) 268-5593 |
News Archive
A SHEFFIELD patient has become the first in the world to take part in a new drug research trial aiming to better control secondary breast cancer, or cancer which has spread to other parts of the body including the bones, liver and lungs for longer.
Results from a new study show that amlodipine-based (calcium channel blocker) treatment is much more effective at reducing blood pressure near the heart than a conventional atenolol-based (beta blocker) regimen.
A team of scientists at the Weizmann Institute of Science in Israel revealed that the ability to detect smells predicts recovery and long-term survival in patients who had a severe brain injury. The study, published in the journal Nature, shows that the simple "sniff test," which is inexpensive and convenient, could help doctors to diagnose and develop treatments for patients who have brain injuries and unconsciousness.
Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.
Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.
› Verified 5 days ago